Bergen, Norway and Oslo, Norway, 30 June 2025 - BerGenBio ASA (OSE: BGBIO) ("BerGenBio" or the "Company") and Oncoinvent ASA (OSE: ONCIN) ("Oncoinvent") announce that they have entered into a merger ...

This offers hope to some patients who face an average survival rate of just several months. Read more at straitstimes.com.

Oncoinvent ASA, a clinical-stage radiopharmaceutical company developing innovative treatments for solid cancers, is thrilled to announce positive topline data from the phase 1/2a clinical trial ...

Bengaluru: What began as a celebration turned into tragedy — and for months, a slice of cake was wrongly blamed. A final ...

ASCO 2025 overall survival data bolster IMNN-001's potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of ...

Data demonstrate sustained peritoneal disease control and reinforce the potential of Oncoinvent's novel radiopharmaceutical therapy to target peritoneal disease in colorectal cancer OSLO ...

Peritoneal mesothelioma starts in the cells that make up the mesothelial lining of the abdominal cavity and typically spreads diffusely in the abdominal area.

Drug delivery systems can alter drug clearance from the peritoneal cavity and drug toxicity profiles. For example, IP injection of cisplatin-loaded polymeric microspheres (100–200 µm, which ...

Absorption of water and electrolytes from the peritoneal cavity has also been demonstrated in human beings. 5,6,13 Dehydrated children absorb up to 500 ml. of physiologic saline solution in less ...